Target intelligence / Profile preview

Intracellular spread protein IcsA (IcsA)

Target
IcsA
Molecular classification
Autotransporter, Adhesin, Outer membrane protein, Type Va secretion system protein
01

Overview

Intracellular spread protein IcsA, also known as VirG, is a 120 kDa outer membrane autotransporter protein primarily found in Shigella species, such as Shigella flexneri [1, 2]. It plays a pivotal role in bacterial pathogenesis by mediating actin-based motility, which allows the pathogen to move within the host cell cytoplasm and spread to adjacent cells [3, 5]. IcsA achieves this by polarly localizing on the bacterial surface and recruiting host cell factors, specifically neural Wiskott-Aldrich syndrome protein (N-WASP) and the Arp2/3 complex, to trigger actin polymerization [3, 12]. This process forms actin comet tails that propel the bacteria, facilitating the formation of protrusions and subsequent infection of neighboring cells [8, 13]. Additionally, IcsA functions as an adhesin and is involved in biofilm formation and the evasion of host autophagy by interacting with proteins like IcsB and Atg5 [1, 4, 7]. Because it is essential for virulence and conserved across various serotypes, IcsA is a major target for the development of vaccines, such as multiepitope fusion antigens (MEFA), and anti-virulence therapies aimed at disrupting bacterial dissemination [4, 11]. Experimental inhibitors like A22 and MP265 have been shown to disrupt its polar localization, highlighting its potential as a therapeutic target [6, 9].

Other names
VirGVirulence gene G proteinAutotransporter protein IcsAIcsA autotransporter
02

Mechanism of action

Inhibition of polar localization, blocking of N-WASP recruitment, or induction of neutralizing antibodies to prevent bacterial adhesion and spread.

03

Biological functions

Actin-based motilityCell-to-cell spreadBacterial adhesionBiofilm formationAutophagy evasion
04

Disease associations

InfectionShigellosisBacillary dysentery
05

Safety considerations

High sequence variability in some regionsRequirement for precise polar localization for therapeutic efficacyPotential for bacterial compensation mechanisms
06

Interacting drugs

A22 (experimental)

3 more in the full profile.

07

Biomarkers

Anti-IcsA antibodiesIcsA protein expression in clinical isolates

Beyond the preview

Go deeper on Intracellular spread protein IcsA (IcsA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intracellular spread protein IcsA (IcsA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call